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Abstract
Background: Different approaches have been used in case-control studies to estimate maternal exposure to medications
and the risk of birth defects. However, the performance of these approaches and how they affect the odds ratio (OR)
estimates have not been evaluated using birth-defect surveillance programmes. The aim of this study was to evaluate the
scope and limitations of three case-control approaches to assess the teratogenic risk of birth defects in mothers exposed to
antiepileptic medications, insulin, or acetaminophen.
Methodology/Principal Findings: We studied 110,814 non-malformed newborns and 58,514 live newborns with birth
defects registered by the Latin American Collaborative Study of Congenital Anomalies (ECLAMC) between 1967 and 2008.
Four controls were randomly selected for each case in the same hospital and period, and three different control groups
were used: non-malformed newborns (HEALTHY), malformed newborns (SICK), and a subgroup of SICK, only-exposed cases
(OECA). Associations were evaluated using OR and Pearson’s chi-square (P,0.01). There were no concordance correlations
between the HEALTHY and OECA designs, and the average OR differences ranged from 3.0 to 11.5 for the three evaluated
medicines. The overestimations observed for HEALTHY design were increased as higher OR values were given, with a high
and statistically significant correlation between the difference and the mean. On the contrary, the concordance correlations
obtained between the SICK and OECA designs were quite good, with no significant differences in the average risks.
Conclusions: The HEALTHY design estimates the true population OR, but shows a high rate of false-positive results
presumably caused by differential misclassification bias. This bias decreases with the increase of the proportion of exposed
controls. SICK and OECA odds ratios cannot be considered a direct estimate of the true population OR except under certain
conditions. However, the SICK and OECA designs could provide practical information to generate hypotheses about
potential teratogens.
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Introduction
Different case-control study designs have been used to estimate
the risk of birth defects after medication exposure. These
approaches differ in their definition and selection of the control
group. Case-control studies with healthy newborn controls are
widely used, especially for studying rare events such as birth
defects. In South America, the Latin American Collaborative
Study of Congenital Anomalies (ECLAMC) has maintained a
surveillance programme for birth defects since 1967 using a case-
control design [1].
However, as has been laid out in previous works [2–7], these
risk estimates from case-control studies are vulnerable to selection
bias, confounding bias, and information bias (differential misclas-
sification bias). In this sense, recall and interviewer bias (two types
of information bias) are subjects of great concern in birth-defect
epidemiology [8]. Recall bias may occur when mothers of babies
with birth defects carefully report the use of medications or when
they are thoroughly interviewed regarding medicine use as a
possible cause of their infants’ defects. In the latter case, mothers
are more likely to recall medication exposure than are mothers of
healthy controls with similar medication use [9]. Interviewer bias
arises when the interviewers know who are the mothers of cases
and who are the mothers of controls, and then the interviewers
may have a higher tendency to determine the exposure histories of
cases than the exposure histories for controls. Both biases may
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result in the over-estimation of the effect of medication (odds ratio)
and a higher probability of false-positive results. Although previous
studies have found little evidence of differential misclassification of
exposures in case-control studies of birth defects (see refferences in
Swan et al. [10]), potential reporting bias is a reasonable issue to
be considered in studies to assess teratogenic effects of medications.
A useful system have been proposed to post-marketing
surveillance of fetal effects of medications using available sources
from existing birth defect surveillance programs and globally
organized through the International Clearinghouse for Birth
Defects Surveillance and Research (ICBDSR) [11]. Considering
that methodology, coverage, and sources of ascertainment vary
among these birth defects surveillance programs, approaches
based on malformed controls and only-exposed controls has been
suggested as practical designs to disclose potential teratogens [11–
14].
The interpretation and usefulness of the epidemiological
methods that include healthy and malformed controls have been
discussed previously [11,15–18]; however, the performance of
these approaches and how they affect the odds ratio estimates have
not been evaluated using birth-defect surveillance programmes.
The aim of this study was to evaluate, using the ECLAMC’s
surveillance programme, the scope and limitations of three
approaches to assess the teratogenic risk for birth defects in
mothers exposed to specific medications during the first trimester
of pregnancy: (a) antiepileptics, which are medications associated
with a risk of birth defects; (b) insulin, which is a marker for pre-
gestational diabetes, a chronic condition that is well known to be
associated with birth defects; and (c) acetaminophen, which is a
medication that is not associated with birth defects.
Materials and Methods
Sample and case definition
Live-birth cases were those that were registered by the
ECLAMC network, involving 102 maternity hospitals from 11
South American countries from 1967 to 2008 and covering
3,939,474 births. A total of 58,514 live births with isolated or
multiple birth defects were registered with ICD-X BPA codes [19].
Non-isolated (multiple malformed) cases were counted separately
for each type of birth defect. Cases with aetiologic syndromes [20]
and those with only a minor birth defect were excluded.
A total of 110,814 non-malformed newborns from the same
database were used as healthy controls. Data regarding medication
use and illnesses during pregnancy were obtained by qualified
physicians using standard interviews of the mothers before their
discharge from the hospital at which they had given birth. Data
were collected, reviewed and coded by the ECLAMC following
the same standardized procedure used since 1967 [1]. Medicines
were coded with the standard ATC system [21]. The study
protocol was approved by the ethics committee at CEMIC
(DHHS-IRB #1745, IORG #1315).
Medicine exposure
The three medicines analyzed in this study were the following:
antiepileptics (ATC code: N03A), including valproic acid
(N03AG01); insulin (ATC code: A10A); and acetaminophen
(ATC code: N02BE01). Exposures to vitamins and iron were
excluded from the analysis in order to minimize bias, as exposure
to these medications has not been proven to be teratogenic.
Epidemiological Designs
Figure 1a shows the four categories of association between the
medications and types of birth defects in the sample. Risk 1
(MRBD) is the risk that the study medication (‘‘M’’) causes the
birth defect studied (‘‘BD’’); Risk 2 (MROBD) is the risk that the
study medication (‘‘M’’) produces congenital anomalies other than
the birth defect under study (‘‘OBD’’); Risk 3 (OMRBD) is the
risk that other medicines (‘‘OM’’) produce the birth defect studied
(‘‘BD’’); and Risk 4 (OMROBD) is the risk that other medications
(‘‘OM’’) cause other birth defects (‘‘OBD’’). In prospective studies,
these associations could be estimated from the relative risks (RR).
Similarly, in retrospective studies with non-malformed controls,
the magnitude of each of these associations could be estimated by
calculating the corresponding odds ratios (OR). As illustrated by
the three-by-three table in Figure 1b, the ORs for these four
associations are as follows:
OR(M?BD)~
a|i
c|g
ð1Þ
OR(M?OBD)~
b|i
c|h
ð2Þ
OR(OM?BD)~
d|i
f|g
ð3Þ
OR(OM?OBD)~
e|i
f|h
ð4Þ
These indicators are known to be sensitive to reporting bias, so
different approaches including ‘‘malformed’’ and ‘‘only-exposed
cases’’ controls were developed to try to reduce this bias.
Three different case-control designs were used in the present
study:
a) HEALTHY design: This was the classical case-control
design. Cases included those infants with any of the birth
defects (alone or in combination with other birth defects).
Four non-malformed controls were randomly selected for
each case from all healthy newborns registered by ECLAMC
in the same hospital and period. These controls showed no
difference to total births with respect to maternal age,
gravidity, and birth weight (Table S1; supplemental material).
a) Subjects were considered exposed if their mothers reported
the use of the study medicine during the first trimester of
pregnancy (with or without other medications) and were
considered non-exposed when their mothers reported no
medication use. The magnitude of this association (OR-
HEALTHY) was calculated by the same method that was used
for OR(MRBD), (Figure 1b):
ORHEALTHY~
a|i
c|g
ð5Þ
b) SICK design: This was a case-control design in which both
the cases and controls were malformed. The cases were
defined similarly to those in the HEALTHY design. Four
newborns with birth defects other than the case were
randomly selected from all malformed newborns registered
by ECLAMC in the same hospital and period. The operative
definition of exposed versus non-exposed was similar to that
Case-Control Designs to Evaluate Teratogenic Risk
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for the HEALTHY design. The ORSICK was calculated as
follows (Figure 1b):
ORSICK~
a|h
b|g
ð6Þ
c) OECA (Only-Exposed Cases) design: This approach only
included malformed newborns who were prenatally exposed
to any type of medicine, so this is actually a subgroup of
SICK. Cases and controls were defined similarly to those for
the SICK design. Malformed newborns whose mothers
reported the use of the study medication were considered
exposed subjects, and those whose mothers reported the use
of medicines other than the ones studied were included as
non-exposed. The OROECA is represented as follows
(Figure 1b):
OROECA~
a|e
b|d
ð7Þ
Statistical methods and power
Associations between the medicines and birth defects were
assessed using Odds ratios (ORs) and Pearson’s chi-square test at a
level of significance of 1% (P,0.01). Ninety-nine percent
confidence intervals (99% CI) were calculated for all birth defects
in HEALTHY design. Each birth defect was analysed separately
for antiepileptics, insulin, and acetaminophen use during the first
trimester of pregnancy.
For the available sample size and a medicine exposure around
1%, the minimum detectable OR is 2.0, with a power of 90%
when the sample size is 2000 cases and 60% when sample size is
500 cases. Out of the 31 birth defects analysed in the present
study, only two were found in less than 500 cases, and ten were
found in more than 2000 cases.
Lin’s concordance correlation coefficient (rc) [22] was used as a
measure of agreement between the three designs. This method
combined measures of precision and accuracy to determine
whether the ORHELATHY and ORSICK estimates significantly
deviated from the line of perfect concordance with the OROECA
estimates (taken as the baseline). Lin’s coefficient increases in value
as a function of the nearness of the data’s reduced major axis to the
line of perfect concordance (a measure of accuracy of data) and of
the tightness of the data about its reduced major axis (a measure of
precision of data).
Bland-Altman analysis of the limits of agreement [23] was
applied to compare the average difference between the designs,
Figure 1. Prenatal exposure to medications and birth defects occurrence. (a) Potential relationships between prenatal exposure to
medications and birth defects occurrence in the population; (b) Three-by-three contingency table of malformed and non-malformed newborns with
prenatal exposure to the study medication, exposure to other medications, and non-exposed; cell frequencies are represented by the letters a, b, c, d,
e, f, g, h, and i.
doi:10.1371/journal.pone.0046626.g001
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together with the variability of the differences and the overall
trend. The correlation between the difference and mean (rd2m) and
the 95% limits of agreement (95% CI) were estimated and tested
for significance using the Bradley-Blackwood test (F).
Potential reporting/selection biases (in percentages) were
calculated according Swan et al. [10] as follows:
bias(%)~
(ORBi {OR
T
i )
ORTi
|100
where ORB (‘‘biased’’ odds ratio) is the observed OR; ORT
(‘‘true’’ odd ratio) is equals to 1, assuming there is not association
among acetaminophen use and birth defects; and the letter i
indicates SICK, OECA, or HEALTHY designs.
For each design, a linear regression model was applied to
evaluate possible association between the bias and the proportion
of exposed controls to acetaminophen:
bias(%)~b0zb1|Exp(%)ze
where the b0 coefficient is the bias-intercept and the b1coefficient
evaluate the increment of bias as a function of the proportion of
exposed controls (slope of the curve).
All statistical analyses were processed using Stata 12 SE (Stata
Corporation, College Station, Texas).
Results
Medicine exposure during the first trimester of
pregnancy
Out of the 3,939,474 total births that were registered by the
ECLAMC, 58,514 newborns had a non-syndromic birth defect, of
whom 48,971 had a single birth defect (83.7%), and 9,543 had two
or more unrelated major birth defects (16.3%).
Table 1 summarises the frequencies of exposure to medicines
during the first trimester of pregnancy among the malformed and
non-malformed newborns. Twenty-six percent of the malformed
newborns were prenatally exposed to some type of medication,
while this percentage was around 19% among non-malformed
newborns. Similar relative differences were observed between
these groups for exposures to any other medication and for
unknown exposures.
The frequencies of exposure to antiepileptics and insulin for
malformed newborns were more than twice those observed for
non-malformed babies. A minor difference between these groups
was observed in the percentage of exposure to acetaminophen
(Table 1). Considering only the total exposed subjects, 1.91%
(294/15411), 1.48% (228/15411), and 11.60% (1788/15411) of
these infants were prenatally exposed to antiepileptics, insulin, and
acetaminophen, respectively.
Table 2 summarises the rate (per 10,000 births) of 30 birth
defects and the frequency of medicine exposures during the first
trimester of pregnancy registered by the ECLAMC in the study
period.
Concordance among the three case-control approaches
When considering concordance, no significant correlation
between the HEALTHY and OECA designs were observed for
antiepileptics (rc = 0.07; 95%CI: 0.02–0.11), insulin (rc = 0.06;
95%CI: 0.02–0.10), and acetaminophen (rc = 0.02; 95%CI: 0.01–
0.04). The average difference between these designs (OR-
HEALTHY2OROECA) was 6.1 (95%CI: 21.9–14.0) for antiepileptics,
11.5 (95%CI:211.8–34.7) for insulin, and 3.0 (95%CI: 0.98–5.06)
for acetaminophen. The overestimations observed for HEALTHY
design were increased as higher odds ratio values were given, with
high and statistically significant correlations between the difference
and mean (rd2m) for antiepileptics (rd2m = 0.98; F = 863.3;
P,0.001), insulin (rd2m = 0.99; F = 976.9; P,0.001), and acet-
aminophen (rd2m = 0.95; F = 1474.9; P,0.001).
In contrast, significant concordance correlations were obtained
between the SICK and OECA methods for antiepileptics
(rc = 0.95; 95%CI: 0.92–0.98), insulin (rc = 0.98; 95%CI: 0.97–
0.99), and acetaminophen (rc = 0.68; 95%CI: 0.51–0.85). There
were no significant differences in the average values between
ORSICK and OROECA for antiepileptics (0.13; 95%CI: 20.21–0.47),
insulin (0.15; 95%CI: 20.25–0.56), and acetaminophen (0.11;
95%CI: 20.17–0.39).
Significant associations identified by SICK, OECA, and
HEALTHY designs
The associations between each birth defect and exposure to
antiepileptics, insulin, and acetaminophen estimated by the three
case-control designs are presented as smile plots in Figure 2. In
each smile plot, P values are plotted on the y-axis on a reverse log
Table 1. Frequency of exposed to medicines during the first trimester of pregnancy in 58,514 subjects with single or multiple birth
defects (excluding minor anomalies and syndromes) and 110,814 non-malformed newborns.
Malformed newborns Non-malformed newborns
(N=58,514) (N=110,814)
N % (95% CI) N % (95% CI)
Total newborns exposed to medicine1 15,411 26.3 (26.0–26.7) 20,783 18.8 (18.5–19.0)
Exposed to antiepileptics2 (ATC code: N03A) 294 0.50 (0.45–0.56) 254 0.23 (0.20–0.26)
Exposed to insulin2 (ATC code: A10A) 228 0.39 (0.34–0.44) 161 0.15 (0.12–0.17)
Exposed to acetaminophen2 (ATC code: N02BE01) 1,788 3.06 (2.92–3.20) 2,730 2.46 (2.37–2.56)
Exposed to any other medicine 11,286 19.3 (19.0–19.6) 14,897 13.4 (13.2–13.6)
Unknown exposure 4,215 7.20 (7.00–7.42) 5,285 4.77 (4.64–4.89)
Total Non-exposed newborns1 43,103 73.7 (73.3–74.0) 90,031 81.3 (81.0–81.5)
References: (1): Prenatal medication exposure during the first trimester of pregnancy according to maternal report; (2): Exposed to the study medication, alone or in
combination with other medications; (ATC code) Anatomical Therapeutic Chemical classification system.
doi:10.1371/journal.pone.0046626.t001
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scale against the estimated odds ratios on the x-axis. Therefore,
statistically significant positive associations are plotted in the upper
right quadrant of each smile plot.
A significant association between antiepileptics exposure and
Spina bı´fida (Q05) was identified by SICK and OECA approach-
es. While eighteen significant associations (including Spina bifida)
with ORs ranging between 2.8 and 18.3 were observed using
HEALTHY design (see Figure 2, row 1). Full details of odds ratios,
P values and 99% CI estimates for the association between the
antiepileptic medications and each birth defect by the three
approaches are shown in Table S2 (supplemental material).
Atrial septal defect (Q21.1), axial skeletal malformations (Q67.5;
Q76.0–Q76.8), severe ear malformation (Q16.0 and Q17.2), and
ventricular septal defect (Q21.0) showed a strong association with
insulin exposure using SICK and OECA approaches. Fifteen
significant associations (including the four birth defect groups
described above) with ORs ranging between 4.2 and 74.6 were
identified by HEALTHY design (Figure 2, row 2). All odds ratios,
P values, and 99% CI for insulin and each birth defect are
presented in Table S3 (supplemental material).
There were no significant associations between the birth defects
and acetaminophen (paracetamol) using the SICK and OECA
designs, with the unique exception of a negative association
(OR,1) with multiple joint contractures (Q74.3) using OECA
approach. On the other hand, twenty-nine significant associations
with ORs ranging between 2.3 and 6.3 were observed using
HEALTHY design (Figure 2, row 3). Details of all odds ratios, P
values, and 99% CI for acetaminophen exposure are shown in
Table S4 (supplemental material).
Table 3 summarizes the statistically significant results obtained
using SICK or OECA approaches. The estimated OR and P
values are shown for SICK and OECA designs, while OR and
Table 2. Number of cases; rate per 10,000 births; and frequencies of exposed to antiepileptics, insulin, and acetaminophen
registered by the ECLAMC during 1967–2008.
Prenatal Medication Exposure1
Cases Antiepileptics Insulin Acetaminophen Others
Birth Defects N Rate2 N % N % N % N %
Ambiguous genitalia/Intersexual organs, ambiguous 592 1.5 6 1.0 4 0.7 18 3.0 146 24.7
Anencephaly 1,262 3.2 6 0.5 4 0.3 27 2.1 291 23.1
Anophthalmia 527 1.3 2 0.4 3 0.6 17 3.2 126 23.9
Anorectal atresia/stenosis 1,509 3.8 6 0.4 3 0.2 47 3.1 307 20.3
Atrial septal defect 560 1.4 6 1.1 7 1.3 34 6.1 107 19.1
Axial skeleton malformation 615 1.6 4 0.7 14 2.3 12 2.0 150 24.4
Cardiac left ventricle obstructive defect 548 1.4 1 0.2 9 1.6 20 3.7 115 21.0
Cardiac outflow tract defect 496 1.3 3 0.6 7 1.4 14 2.8 96 19.4
Cardiac right ventricle obstructive defects 615 1.6 3 0.5 2 0.3 27 4.4 119 19.4
Cleft lip with or without paIate 4,267 10.8 32 0.8 11 0.3 115 2.7 838 19.6
Cleft paIate (included Pierre Robin) 1,439 3.7 13 0.9 6 0.4 49 3.4 295 20.5
Cystic kidney 918 2.3 8 0.9 6 0.7 49 5.3 193 21.0
Encephalocele 720 1.8 4 0.6 4 0.6 27 3.8 172 23.9
Gastroschisis 935 9.5 1 0.1 1 0.1 31 3.3 160 17.1
Hip dislocation 5,432 13.8 15 0.3 9 0.2 116 2.1 1061 19.5
Hydrocephaly 3,072 7.8 13 0.4 8 0.3 125 4.1 649 21.1
Hydronephrosis - Ureter stenosis/atresia 2,025 5.1 15 0.7 6 0.3 107 5.3 424 20.9
Hypospadias 3,390 8.6 22 0.7 11 0.3 122 3.6 701 20.7
Intestinal atresia/stenosis 928 2.4 7 0.8 6 0.7 37 4.0 191 20.6
Levo transposition of great arteries 318 0.8 0 0.0 6 1.9 11 3.5 58 18.2
Limb reduction defect 2362 6.0 8 0.3 7 0.3 65 2.8 583 24.7
Microcephaly 1,096 2.8 10 0.9 10 0.9 23 2.1 207 18.9
Multiple malposition/contractures 894 2.3 5 0.6 1 0.1 20 2.2 207 23.2
Oesophageal atresia/stenosis 1,021 2.6 1 0.1 3 0.3 28 2.7 216 21.2
Omphalocele 800 8.1 5 0.6 4 0.5 26 3.3 194 24.3
Patent Ductus Arteriosus 375 1.0 2 0.5 5 1.3 15 4.0 72 19.2
Severe ear malformation 1,838 4.7 3 0.2 13 0.7 46 2.5 362 19.7
Spina bifida 3,058 7.8 29 1.0 5 0.2 94 3.1 625 20.4
Unilateral/Bilateral kidney a/dysgenesis 524 1.3 2 0.4 8 1.5 20 3.8 118 22.5
Ventricular septal defect 2,216 5.6 9 0.4 22 1.0 116 5.2 372 16.8
References: (1): Prenatal medication exposure during the first trimester of pregnancy according to maternal report; (2) Rate per 10,000 live births.
doi:10.1371/journal.pone.0046626.t002
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99%CI are shown for the four measures of association calculated
from non-malformed controls.
Potential bias in each approach
Figure 3 shows bias as a function of the proportion of exposed
controls to acetaminophen for 31 birth defect groups in the SICK,
OECA, and HEALTHY designs.
The average proportions of exposure to acetaminophen in the
31 control groups (6 SD) were 4.6% (61.2); 12.9% (62.9); and
1.3% (60.4) for SICK, OECA, and HEALTHY design,
respectively. While the mean biases (6 SD) were 2.6% (621.7)
for SICK; 28.4% (620.0) for OECA; and 293.4% (6112.1) for
HEALTHY design.
No significant associations between the proportion of exposed
controls and bias were detected for SICK (b1 coeff. =24.93;
P = 0.127), and OECA (b1 coeff. =20.81; P = 0.526) approaches,
with overall R-squared of 0.08 (F = 2.46; P = 0.127) and 0.01
(F = 0.41; P = 0.525), respectively. On the other hand, a significant
decrease in bias with the increasing proportion of exposed controls
was observed for HEALTHY design (b1 coeff. =2141.0;
P = 0.002), with an overall R-squared of 0.28 (F = 11.3; P = 0.002),
In addition we have calculated the associations between
acetaminophen and each of 31 birth defects by the four odds
ratios that use non-malformed controls (see Figure 1 and formules
1 to 4). The average odds ratio (6 SD) between acetaminophen
and the birth defects studied (MRBD) was 3.9 (61.1). Between
acetaminophen and congential anomalies other than the birth
defect under study (MROBD) was 3.9 (60.9). Furthermore, the
average odds ratio observed for other medications and the birth
defect studied (OMRBD) was 4.9 (60.8), and for other
medications and other birth defects (OMROBD) was 4.4 (60.3).
Discussion
This study evaluates the scope and limitations of three different
approaches used to assess the teratogenic risk of prenatal exposure
to medications, applying these methods to the data from
ECLAMC’s birth-defect surveillance programme. For this pur-
pose, the association between the use of three well-known
medicines during the first three months of pregnancy and the
risk for 31 types of birth defects were assessed by means of case-
control methodology using three types of controls: non-malformed
newborns (‘‘HEALTHY’’ design), malformed newborns (‘‘SICK’’
design), and malformed newborns exposed to certain medications
(‘‘OECA’’ design).
Figure 2. Associations between medications and birth defects for SICK, OECA and HEALTHY designs. The smile plots summarize the
associations between each birth defect and exposure to antiepileptics, insulin, and acetaminophen for the three case-control designs. In each smile
plot, P-values are plotted on the y-axis on a reverse log scale against the estimated odds ratios on the x-axis. So, the higher the P-values up the y-axis
the more significant they are. The vertical full red line represents no association between medication exposure and birth defect (OR equals to 1), and
the horizontal dashed red line represents the cut-off P value (0.01).
doi:10.1371/journal.pone.0046626.g002
Case-Control Designs to Evaluate Teratogenic Risk
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Methodological considerations: measures of the
association for the HEALTHY, SICK, and OECA designs
The interpretation of the measures of association obtained with
the different methodological approaches using non-malformed,
malformed, or exposed malformed newborns as the control groups
in the research on medication teratogenicity has been extensively
discussed [11–13,15,16,24]. Although some of the formulas
displayed in this work (from No. 1 to No. 14) are certainly basic,
we summarised this discussion and applied these basic concepts to
real data from a birth defects surveillance programme in order to
better understand the relationships among these measures.
Table 3. Statistically significant results obtained using SICK or OECA approaches.
Malformed Controls Non-malformed Controls
SICK OECA HEALTHY (MRBD)1 (MROBD)2 (OMRBD)3 (OMROBD)4
Birth Defect Exposure5 OR P value OR P value OR (99% CI) P value OR (99% CI) OR (99% CI) OR (99% CI)
Spina bı´fida ANTI 1.8 0.006 1.9 0.003 12.3 (5.1–30.0) ,0.00001 6.6 (2.9–14.9) 4.6 (4.0–5.2) 4.5 (4.0–5.0)
Severe ear
malformation
INSU 3.4 0.001 2.9 0.005 33.0 (4.6–234.6) ,0.00001 9.9 (1.4–68.2) 5.0 (4.2–6.0) 4.3 (3.7–4.9)
Ventricular septal
defect
INSU 2.1 0.005 2.4 0.001 55.5 (8.2–373.3) ,0.00001 26.2 (4.0–169.7) 3.9 (3.3–4.6) 4.4 (3.9–5.0)
Atrial septal defect INSU 5.8 0.003 5.2 0.006 18.3 (2.3–145.3) ,0.001 3.2 (0.4–27.3) 4.4 (3.2–6.0) 3.9 (3.0–4.9)
Axial skeletal
malformations
INSU 5.3 ,0.0001 4.7 0.002 74.6 (5.1–689.8) ,0.00001 14 (3.2–96.7) 4.8 (3.6–6.5) 4.3 (3.4–5.4)
Multiple joint
contractures
ACET 0.7 0.082 0.5 0.003 4.9 (2.2–10.9) ,0.00001 7.5 (4.1–13.6) 5.9 (4.5–7.6) 4.3 (3.5–5.3)
References: (1): (MRBD) is the risk that the study medication (‘‘M’’) causes the birth defect studied (‘‘BD’’); (2): (MROBD) is the risk that the study medication (‘‘M’’)
produces congenital anomalies other than the birth defect under study (‘‘OBD’’); (3): (OMRBD) is the risk that other medicines (‘‘OM’’) produce the birth defect studied
(‘‘BD’’); (4): (OMROBD) is the risk that other medications (‘‘OM’’) cause other birth defects (‘‘OBD’’); (5): Exposure: (ANTI) antiepileptic medications, (INSU) insulin, (ACET)
acetaminophen.
doi:10.1371/journal.pone.0046626.t003
Figure 3. Bias in SICK, OECA and HEALTHY designs. The potential bias (%) is shown as a function of the proportion of exposed controls to
acetaminophen (%) in the 31 birth defect groups and for the three evaluated designs. The linear function is defined as follows:
Bias(%) = b0+b1*Exp(%); R-squared (R2) and the overall P value for the regression model are shown for each design.
doi:10.1371/journal.pone.0046626.g003
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Beyond the control group used, these risk estimates from case-
control studies of birth defects are vulnerable to both reporting
bias and selection bias ([10,18,25]. Although effects of selection
and reporting bias on the odds ratio are expected to act in opposite
directions and it could be difficult to predict in each particular
design which are of greater magnitude, both are shown to be
algebraically equivalent [10]. Thus, both sources of bias could be
combined through a unique term and any of the types of
association (Figure 1) estimated by each OR calculated from the
formulas (1) to (7) could be expressed as follows:
ORBi ~OR
T
i |ki ð8Þ
where the observed (‘‘biased’’) odds ratio (ORB) depends on the
true value (ORT) and k that indicates the effect of bias on the
estimated measures of association for each particular approach (i).
If cases and non-malformed controls have differential mis-
sclasification bias (reporting bias), then ki.1 and the OR
B will over-
estimate the true ORT. If, however, malformed controls are used
and at least some of the malformations in the control group were
positively associated with the study medication, this introduces a
selection bias so-called teratogenicity non-specific bias [18], then
ki,1 and the OR
T will be under-estimated. Another possibility is
that cases and non-malformed controls have poor recall but with
non-differential misclassification bias of exposure; or that the use
of malformed controls could be to balance out the selective recall
by parents of cases, then ki<1 and the effect of bias could be
considered negligible.
It is important to note that the ki term is a function of the ratio of
the observed odds of exposure to the true odds of exposure in cases
to that in controls. Therefore, it is equivalent to the ‘‘selection odds
ratio’’ describe by Kleinbaum [26] and to the inverse of ‘‘gamma’’
(c) defined by Swan et al. [10].
HEALTHY design. This is the classic retrospective case-
control design (Figure 1). Considering the formulas (1), (5), and
(8), ORHEALTHY can be expressed as follows:
ORHEALTHY~OR
B
(M?BD)~OR
T
(M?BD)|k(M?BD) ð9Þ
Therefore, this design is unable to reduce the bias (k(MRBD)) or
quantify the magnitude of bias on the estimated ORHEALTHY,
unless the measurement of prenatal exposure has been collected
before the birth-defect diagnosis (a prospective cohort design as a
‘‘gold standard’’).
Our results showed high-sensibility and low-specificity to detect
significant associations between each of the three medications and
each birth defect using HEALTHY approach. Furthermore, the
overestimations that were observed using this design were
increased with higher odds ratios. Thus, we might assume that
most of these associations are false positive results caused by
differential misclassification bias (maternal recall bias or ascertain-
ment bias by the interviewer).
We have shown also that, at least in the case of acetaminophen,
this bias effect inflates in average near to 300 percent the odds
ratio and that the bias decrease with the increase of proportion of
exposed controls. Therefore, if this bias acts in a similar way for
different exposures, we expect a higher bias effect for rare
medications. This interpretation is in agreement with our
observations for antiepileptics and insulin, which have showed
very low proportion of exposed and high odds ratios estimated by
HEALTHY design for the majority of evaluated birth defects.
The main advantage of using non-malformed controls in
retrospective studies of potential teratogens is the possibility of
estimating the ‘‘true’’ population odds ratio, but as it is shown in
this and previous papers [10,15], the effects of bias on the observed
odds ratio could be considerable and difficult to quantify. One
possible approach to quantify this bias when non-malformed
controls are used, is to calculate the four associations that has been
proposed in this work (formules 1 to 4), under the hypothesis that
reporting bias should affect in a similar way the four odds ratios. In
this paper, acetaminophen exposure showed average odds ratios
around 4 for these associations, showing the lack of specificity of
the association between acetaminophen and the study birth defect
(MRBD), acetaminophen and other birth defects (MROBD), of
other medications and the birth defect studied (OMRBD), and
other medications with other birth defects (OMROBD). We may
regard this value as a rough measure of the magnitude of the
overestimation due to reporting bias in this particular study and to
use it to adjust the observed measure of association between the
study medication and the birth defect studied (MRBD).
Our results are in agreement with the estimate of reporting bias
for the retrospective ascertainment of exposure reported by Bar-
Oz et al. [15]. These authors investigated the recall bias for
itraconazole exposure at least during the first trimester of
pregnancy using pharmaceutical-industry data by comparing two
cohorts, retrospective and prospective. The authors showed that
the chances of the occurrence of a major birth defect after first-
trimester exposure to itraconazole were four times higher when
the woman or her physician filed the report during the postpartum
period than when women were followed up prospectively. As
expected, the authors showed that women whose children have
major birth defects, or their physicians, are more likely to report
the ‘‘exposure’’ than those with healthy newborns.
SICK design. This approach uses malformed newborns as
the control group. Based on equations (1), (2), (6), and (8),
ORSICK can be expressed as follows:
ORSICK~
ORB(M?BD)
ORB(M?OBD)
~
ORT (M?BD)|k(M?BD)
ORT (M?OBD)|k(M?OBD)
ð10Þ
If minor birth defects and well-known associations were excluded
from the analysis, and the biases were therefore dependent on the
type of medication but to a lesser extent on the birth defect
studied, then k(MRBD)<k(MROBD), and consequently:
ORSICK~
ORT (M?BD)|k(M?BD)
ORT (M?OBD)|k(M?OBD)
&
ORT (M?BD)
ORT (M?OBD)
ð11Þ
Therefore, the ORSICK is a measure of the relationship between the
risk of the study medication causing the birth defect studied
(MRBD) and the risk of the study medication producing
congenital anomalies other than the birth defect under study
(MROBD). This ORSICK is then a measure of the teratogenic
specificity of the medication, as previously reported [16]. If the
medicine under study is associated with other birth defects, this
introduces a type of selection bias known as teratogenicity non-
specific bias [18], and then the SICK approach under-reports the
true odds ratio. However, if the medications under study has a
specific teratogenic effect, then ORT(MROBD)<1 and ORSICK will be
a good approximation of the true odds ratio of interest
(ORT(MRBD)).
In the present work, acetaminophen exposure showed no
significant associations using SICK approach with average odds
ratios around 1.0. Moreover, the observed average bias could be
considered negligible (2.6%) with no relationship with the
frequency of exposure. Thus, unlike ORHEALTHY, this approach
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affords the opportunity, under certain assumptions, to reduce the
effect of reporting bias on the measure of association. Although it
is important to reiterate that ORSICK is not a direct estimate of the
true population odds ratio unless there is no association between
the medications and other birth defects.
OECA design. This methodology uses malformed newborns
exposed to certain medications as the control group. We can
develop the previous formulas (1), (2), (3), (4), (7), and (8), and
OROECA can be expressed as follows:
OROECA~
ORB(M?BD)|OR
B
(OM?OBD)
ORB(M?OBD)|OR
B
(OM?BD)
~
ORT(M?BD)|k(M?BD)|OR
T
(OM?OBD)|k(OM?OBD)
ORT(M?OBD)|k(M?OBD)|OR
T
(OM?BD)|k(OM?BD)
ð12Þ
Similar to the SICK design, if the bias is mainly dependent on the
kind of medication, then k(MRBD)<k(MROBD) and k(OMRBD)
<k(OMROBD). On the other hand, if the bias is mainly dependent
on the type of birth defect, then k(MRBD)<k(OMRBD) and k(MROBD)
<k(OMROBD). Under either of these two scenarios, the measure of
association can be expressed as follows:
OROECA~
ORT(M?BD)|k(M?BD)|OR
T
(OM?OBD)|k(OM?OBD)
ORT(M?OBD)|k(M?OBD)|OR
T
(OM?BD)|k(OM?BD)
&
ORT(M?BD)|OR
T
(OM?OBD)
ORT(M?OBD)|OR
T
(OM?BD)
ð13Þ
Thus, as previously reported [24], the magnitude of this
association depends on a complex relationship between the risk
of the study medication to cause the birth defect studied (MRBD),
the risk of other medications to cause other birth defects
(OMROBD), the risk of the study medication to produce
congenital anomalies other than the birth defect under study
(MROBD), and the risk of other medicines to produce the birth
defect studied (OMRBD).
Despite this complex relationship, if the study medication has a
specific teratogenic effect (ORT(MRBD).1 and OR
T
(MROBD)<1),
and well-known associations are excluded from the analysis
(ORT(OMROBD)<1), then OROECA will be almost equal to the
quotient between ORT(MRBD) and OR
T
(OMRBD). Therefore, the
OROECA could be a measure of the degree of aetiological specificity
of the defect under study. Then, if the study birth defect were
related to other medications, the OECA approach would under-
estimate the odds ratio of interest (ORT(MRBD)). However, when
the study medication is a major cause of the birth defect under
study (ORT(MRBD).1 and OR
T
(OMRBD)<1), then OROECA will be a
good approximation of the true population odds ratio.
In the present study, acetaminophen exposure showed no
significant associations using OECA approach and the observed
average odds ratio slightly under-estimated the expected value of
1.0. Thus, as for the SICK approach and under certain
assumptions, the OECA design could reduce the effect of bias
on the measurement of association. Nevertheless, it cannot be
considered a direct estimate of the true population odds ratio
except under certain conditions as described above.
SICK vs. OECA designs
Under certain assumptions described in the formulas (11) and
(13), the relation between ORSICK and OROECA can be expressed as
follows:
OROECA&ORSICK|
ORT (OM?OBD)
ORT (OM?BD)
ð14Þ
From this relation, and taking into account our results, some
general considerations can be outlined:
If the observed odds ratios for the SICK and OECA designs are
similar, then it can be inferred that the odds ratio between other
medications and other birth defects is equivalent to the odds ratio
between other medications and the birth defect under consider-
ation (ORT(OMROBD)<ORT(OMRBD)). This was observed in our
results, where good concordance correlations were found between
SICK and OECA designs for atiepileptics, insulin and acetamin-
ophen. Among the significant associations found, this was mainly
evident in the case of antiepileptic and spina bifida.
If OROECA.ORSICK, then it can be concluded that other
medication are associated with other birth defects to a greater
extent than with the birth defect under study (ORT(OMROBD)
.ORT(OMRBD)). This was observed, for example, for insulin and
ventricular septal defects although with small differences in
absolute values.
On the other hand, if OROECA,ORSICK we would expect the
opposite relationship (ORT(OMROBD),OR
T
(OMRBD)). While only
minor differences were observed among the significant associations
found, this was the case for, e.g. insulin and severe ear
malformation, atrial septal defect, and axial skeletal malforma-
tions; and for acetaminophen and multiple joint contractures.
If other medication are associated with other birth defects in a
different extent than with the birth defect under study (ORT
(OMROBD)?OR
T
(OMRBD)), then only OECA is affected while the
SICK is not.
If the study medication is associated with other birth defects
apart from the one studied (ORT(MROBD).1), then both SICK and
OECA will under-estimate the true population odds ratios of
interest (ORT(MRBD)).
In view of these considerations and the results discussed in the
present work, it is important to exclude all known associations
between medications and birth defects from the control groups
before obtaining odds ratios values using SICK and OECA
designs.
Findings and comparison of results
Antiepileptics. The three approaches identified the recog-
nised association between anti-epileptic exposure during pregnan-
cy and spina bifida. When we used HEALTHY design the odds
ratio for spina bifida was twelve times higher than for non-exposed
mothers. A cohort study in Finland [27] found a relative risk for
spina bifida of 11.3 (95%CI: 2.3–108), which is similar to that from
our findings, despite the low accuracy of the estimator. Other
recent studies using malformed controls found significant associ-
ations between spina bifida and monotherapy with valproic acid
[14,28] and with carbamazepine [29]. Furthermore, using
‘‘exposed case-only’’ (like our OECA approach) and data from
twelve registries of congenital birth defects (including ECLAMC),
Lisi et al. [11] found significant associations between spina bifida
and fatty acid (mainly valproic acid); carboxamide, and other
antiepileptic medications.
In the present paper, spina bifida was the only birth defect
significantly associated with antiepileptic medications using both
SICK and OECA approaches. In addition to spina bifida,
previous studies found significant associations between antiepilep-
tics exposure and cardiac defects, cleft lip with or without cleft
palate, hypospadias, anomalies of brain, anomalies of circulatory
ð13Þ
ð12Þ
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system, limb reduction defects, and hypertelorism [14]; and
between antiepileptics exposure and hypospadias, cleft lip with or
without cleft palate, polydactyly, cardiac outflow tract defects, cleft
palate, limb deficiency, atrial septal defect, and craniosynostosis
using OECA design [11].
Insulin. Insulin was used as an indicator of clinically
significant diabetes, a well-known teratogen that can produce
different types of birth defects (see review by Stothard et al. [30]).
Severe ear malformation, ventricular septal defect, atrial septal
defect, and axial skeletal malformations were significantly associ-
ated with insulin by SICK, OECA and HEALTHY designs in our
work. With the exception of the first one, all of these associations
were in agreement with Lisi et al. [11], who only used the OECA
design. Unlike previous reports [11,30,31], no relevant associa-
tions were detected in our study for cardiac defects, kidney a/
dysgenesis, patent ductus arteriosous, holoprosencephaly, choanal
atresia, and levo transposition of great arteries.
Acetaminophen. For acetaminophen exposure, no signifi-
cant associations were detected using the SICK design, while an
unexpected negative association was found with multiple joint
contractures using the OECA approach. The higher odds ratios
observed for acetaminophen and other birth defects (OR(MROBD)),
and for other medications and multiple joint contractures
(OR(OMRBD)) in relation to the two odds ratios in the denominator,
could explain this last finding.
Moreover, using HEALTHY design, twenty-nine birth defects
were significantly associated with acetaminophen exposure. These
results disagree with a recent study conducted by the NBDPS
(National Births Defects Prevention Study, USA) that showed that
single-ingredient acetaminophen use during the first trimester of
pregnancy does not appear to increase the risk for major birth
defects [32]. Whereas acetaminophen has no proven teratogenic
effect [33], the HEALTHY design in our study increased the
number of false-positive associations compared to SICK and
OECA designs. Interestingly, we also observed that this bias
increases with decreasing proportion of exposed controls. There-
fore the differences between the NBDPS study [32] and our study
using the HEALTHY design could be related to the ascertainment
of exposure and a different selection of controls. While NBDPS
reported an average frequency of exposure of 46.9% in cases and
45.8% in controls, we observed frequencies of 3.06% and 2.46%,
respectively. The NBDPS study assigned the exposure as ‘‘single-
ingredient acetaminophen’’ consumption according to maternal
medication use and the information of the Slone Epidemiology
Center Drug Dictionary, which identifies product-specific ingre-
dients. While we used a seven-digit ATC code (N02BE01) that
could be a more specific exposure classification than that used in
the NBDPS study, the use of other drugs together with
acetaminophen cannot be ruled out in our study. In addition,
the NBDPS study selected the controls from population-based
registries, while our work used non-malformed controls from a
hospital-based registry.
Finally, the partial discrepancies between our results for the
three medications evaluated and previous reports could be due to
differences in the sample size, differences in reporting the
exposure, differences in the definition of the exposure, differences
in the use of a specific medication in different countries, and
chance or true differences in exposure risks.
Strengths and pitfalls
An important issue discussed here is the selection of control
group as a potential source of bias. In this regard, it is interesting to
consider the strengths and pitfalls of the present work under the
framework of the three principles of comparability described by
Wacholder et al. in their classical series of papers [2–4]: (1) the
study base principle, (2) the deconfounding principle, and (3) the
comparable accuracy principle.
Because the ECLAMC is a hospital-based program the trade-
off between principles No. 1 and No. 3 is a reasonable concern,
thus selection bias and information bias cannot be completely
discarded. But while the selection bias could affect especially
the malformed cases due to referral of prenatally diagnosed
cases to hospitals serving high-risk pregnancies; we expect that
the referral it be independent of the exposure assessment.
Furthermore, the non-malformed controls registered by
ECLAMC are not the typical ‘‘hospital controls’’, that is to
say, that were hospitalized for some different disease than cases,
but they are selected from the total newborns from each
hospital that participates in the ECLAMC program. Thus, the
controls are also independently selected of the exposure
assessment. In the present work, the non-malformed controls
were randomly selected from all healthy newborns registered by
ECLAMC in the same hospital and period of time (year) as the
cases, and they showed no difference to total births with respect
to maternal age, gravidity, and birth weight. In this sense, given
that more than 95 per cent of births in South America occur in
hospitals, it could be expected that these cases and non-
malformed controls are representative samples from the same
study population (‘‘the study base’’). With regards to principle
No. 2, it is plausible that confounding structure may be specific
for the study base of each hospital and period of time. Because
the confounding by a factor is theoretically eliminated by
eliminating variability in that factor, we have selected a random
sample of controls born in the same hospital and same year as
cases (case-control ratio of 1:4) to try to control most of the
underlying confounding structure.
Another potential pitfall could be that the medications were
grouped as acetaminophen, antiepileptics (irrespective of the type
of medication), and insulin as a proxy for diabetes. However, we
believe there is no major limitation because this study attempts to
analyse the performance of case-control studies using three types
of controls and does not evaluate the biological significance of the
medication exposures and birth defects.
The main strengths in this study are the standardised method in
the diagnostic procedures for all malformed and healthy newborns
included in the study, and the standardised procedure for
medications reported using ATC codes. In addition, medicines
and birth defects were reviewed and coded centrally.
Conclusion
Case-control designs using three control types were compared.
The approach using non-malformed controls (HEALTHY)
showed a high rate of false-positive results presumably caused by
differential misclassification bias. We have shown also that, at least
in the case of acetaminophen, this bias decreases with the increase
of the proportion of exposed controls. The methods using
malformed (SICK) or only-exposed cases (OECA) showed a good
concordance for antiepileptics, insulin and acetaminophen. Both
approaches could yield similar results, depending on the relation-
ship of the other medications with other birth defects (OM-
ROBD), and the relationship of other medications with the birth
defect under study (OMRBD).
SICK and OECA odds ratios cannot be considered a direct
estimate of the true population odds ratio except under certain
conditions. However, the SICK design could be effective to
determine the teratogenic specificity of the medication, whereas
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the OECA approach could be useful to estimate the aetiological
specificity of the defect under study.
In birth defect surveillance programs that have not access to
recruit non-malformed controls, the comparison between SICK
and OECA designs could provide practical information to
generate hypotheses about potential teratogens.
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